Dallas’ Gradalis, Inc. has just announced the appointment of a new executive vice president and chief technical officer, Philip B. Maples, Ph.D., who has been with the company since 2005. Maples has garnered over 28 years of professional experience in the fields of international healthcare and biotechnology, and will be bringing his expertise to the management of the company’s product development, manufacturing and quality assurance. His appointment will benefit Gradalis in its commercialization and expansion initiatives in the advancement of cancer therapeutics focused on personalization and patient safety.
The president and CEO of Gradalis, Joseph M. Limber, shared that Maples has been essential to the company’s present success. According to him, Gradalis has brought a considerable number of therapeutics and technologies to completion and that the new EVP and CTO will be playing a big role in helping bring the company’s endeavors to another level of achievements and commercialization.
Before being appointed to his new position in the company, Maples held the title of vice president of technical operations, and was formerly with Baxter Healthcare, US Oncology, CellExSys, and Chromos Molecular Systems. He graduated from the University of Tulsa with a degree in microbiology, and earned his M.S. and Ph.D. in biochemistry and molecular biology from the University of Oklahoma Health Sciences Center. It was from the University of Chicago that he finished his post-doctoral fellowship.
It’s also worth noting that Gradalis has been making news lately in terms of new appointments to their executive staff. Back in late May, BioNews Texas profiled the appointment of Mr. Limber himself as President and CEO of the company. At the time, Limber talked at length in the company’s press release about the company’s concerted effort to continue development of FANG™, the company’s leading tumor based, personalized cancer vaccine that delays the risk of recurrence by one year in advanced-stage ovarian cancer patients. Dr. Maples’ appoint will undoubtedly work towards bolstering the company’s further development of FANG.